Implantable Drug Delivery Systems Market - Forecasts from 2019 to 2024
The implantable drug delivery market is estimated to witness a CAGR of 8.36% to reach US$17.872 billion in 2024 from US$11.039 billion in 2018. The implantable drug delivery systems are placed under the skin to release drugs and fluids directly into the bloodstream without the repeated insertion of needles. The implantable therapeutic systems are mainly approached for the long term, continuous drug administration and controlled release of the medication. The system is well suited for the drug delivery requirements of insulin, steroids, chemotherapeutic drugs, heparin, etc. This system is more steady, effective, safe and reliable than other drug delivery system.
The market is expected to show significant growth during the forecast period owing to the rising awareness among the population regarding the availability of high quality and safer products. Reduced side effects and on-site delivery provided by Implantable Drug Delivery systems will also boost the growth of the market. However, the need for microsurgery to implant the system and stringent regulatory requirements for the implantable drug delivery systems might restrain the growth of the market during the given time frame. Geographically,
North America is expected to hold a significant market share owing to the increasing investments in R&D. Asia-Pacific is also anticipated to be a prominent market on account of the rising healthcare industry.
DRIVERS
Growing preference for minimally invasive procedures.
Rising prevalence of chronic diseases.
RESTRAINTS
Strict government regulations.
INDUSTRY UPDATE
In April 2019, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System.
In July 2018, Boston Scientific Corporation acquired Claret Medical Inc.,
The major players profiled in the Implantable Drug Delivery Systems market include Microchips Biotech, Inc., DSM, TissueGen, SFC Fluidics, Inc., Medtronic, 3M’s Health Care, Boston Scientific Corporation, Bausch and Lomb, PSivida, and Delpor Inc.
Segmentation
The implantable drug delivery systems market has been analyzed through the following segments:
By Type
Non-Degradable Systems
Biodegradable systems
By Mechanism
Diffusion
Magnetic
Chemical
Osmotic
Others
By Application
Oncology
Cardiovascular
Auto Immune disease
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Others
The market is expected to show significant growth during the forecast period owing to the rising awareness among the population regarding the availability of high quality and safer products. Reduced side effects and on-site delivery provided by Implantable Drug Delivery systems will also boost the growth of the market. However, the need for microsurgery to implant the system and stringent regulatory requirements for the implantable drug delivery systems might restrain the growth of the market during the given time frame. Geographically,
North America is expected to hold a significant market share owing to the increasing investments in R&D. Asia-Pacific is also anticipated to be a prominent market on account of the rising healthcare industry.
DRIVERS
Growing preference for minimally invasive procedures.
Rising prevalence of chronic diseases.
RESTRAINTS
Strict government regulations.
INDUSTRY UPDATE
In April 2019, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System.
In July 2018, Boston Scientific Corporation acquired Claret Medical Inc.,
The major players profiled in the Implantable Drug Delivery Systems market include Microchips Biotech, Inc., DSM, TissueGen, SFC Fluidics, Inc., Medtronic, 3M’s Health Care, Boston Scientific Corporation, Bausch and Lomb, PSivida, and Delpor Inc.
Segmentation
The implantable drug delivery systems market has been analyzed through the following segments:
By Type
Non-Degradable Systems
Biodegradable systems
By Mechanism
Diffusion
Magnetic
Chemical
Osmotic
Others
By Application
Oncology
Cardiovascular
Auto Immune disease
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY TYPE
5.1. Non-Degradable
5.2. Biodegradable
6. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY MECHANISM
6.1. Diffusion
6.2. Magnetic
6.3. Chemical
6.4. Osmotic
6.5. Others
7. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY APPLICATION
7.1. Oncology
7.2. Cardiovascular
7.3. Auto Immune disease
7.4. Others
8. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. United Kingdom
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. Israel
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. South Korea
8.5.4. India
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. Microchips Biotech, Inc.
10.2. DSM
10.3. TissueGen
10.4. SFC Fluidics, Inc.
10.5. Medtronic
10.6. 3M’s Health Care
10.7. Boston Scientific Corporation
10.8. Bausch and Lomb
10.9. PSivida
10.10. Delpor Inc.
LIST OF FIGURES
LIST OF TABLES
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY TYPE
5.1. Non-Degradable
5.2. Biodegradable
6. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY MECHANISM
6.1. Diffusion
6.2. Magnetic
6.3. Chemical
6.4. Osmotic
6.5. Others
7. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY APPLICATION
7.1. Oncology
7.2. Cardiovascular
7.3. Auto Immune disease
7.4. Others
8. IMPLANTABLE DRUG DELIVERY SYSTEMS MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. United Kingdom
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. Israel
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. South Korea
8.5.4. India
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. Microchips Biotech, Inc.
10.2. DSM
10.3. TissueGen
10.4. SFC Fluidics, Inc.
10.5. Medtronic
10.6. 3M’s Health Care
10.7. Boston Scientific Corporation
10.8. Bausch and Lomb
10.9. PSivida
10.10. Delpor Inc.
LIST OF FIGURES
LIST OF TABLES
